Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, MISCELLANEOUS

Exactus, Inc. Will Appear on The National Business Show Today at 3PM EDT


DELRAY BEACH, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB:EXDI) (the "Company"), a farmer and manufacturer of hemp-derived phytocannabinoid products, today announced that Emiliano Aloi, President and CEO will appear on the National Business Show that will be broadcasted today at 3PM EDT to discuss its recent acquisitions and direction of the company.

The National Business Show broadcasts out of Beasley Studios in South Florida and can be heard on Super 740am, 103.9FM reaching all South Florida and Web Casted worldwide on www.wsbrradio.com and filmed live on AMP2.TV at 3PM EDT today. The show can also be viewed on You Tube after the LIVE broadcast. The interview will be conducted by show host, Mick Bazsuly. Questions can be emailed in advance to Mickespn@yahoo.com and the call in number is 888-721-0074.

To learn more about Exactus, Inc., visit the website at  www.exactushemp.com.

About Exactus:
Exactus Inc. is dedicated to introducing hemp-derived phytocannabinoid products into mainstream consumer markets. The Company has made investments in farming and has over 200 acres of CBD-rich hemp in Southwest Oregon. The Company is introducing a range of consumer brands, such as Green Goddess Extracts, Phenologie, Paradise CBD and Exactus. Hemp is a legal type of cannabis plant containing less than 0.3% THC (tetrahydrocannabinol), which is the psychoactive component of the cannabis plant. After 40 years of prohibition, the Agricultural Improvement Act of 2018, known as the 2018 Farm Bill, legalized hemp at the federal level. Hemp production will be regulated by the United States Department of Agriculture (USDA) and the states. As a result, in 2019 hemp was generally removed from the Controlled Substances Act (CSA) and enforcement by the Drug Enforcement Administration (DEA).

For more information about Exactus: www.exactusinc.com.

Investor Notice
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under "Risk Factors" in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2018 filed with the Securities and Exchange Commission (the "SEC") on March 29, 2019, and in other periodic and current reports we file with the SEC.  If any of these risks were to occur, our business, financial condition, or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Safe Harbor" below.

Safe Harbor - Forward-Looking Statements
The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic and current filings with the SEC, including the factors described in the sections entitled "Risk Factors", copies of which may be obtained from the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company does not intend to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company Contact:

Andrew Johnson
Chief Strategy Officer
Exactus Inc.
509-999-9695
ir@exactusinc.com  

 


These press releases may also interest you

at 09:05
ELT Sight, Inc. today announced the company has acquired the IP and assets of MLase AG's excimer ophthalmic laser system for glaucoma surgery. MLase manufactures and markets innovative laser systems, including the ExTra ELT Laser and disposable...

at 09:05
GlycoMimetics, Inc. today announced that company executives will provide a corporate update at two upcoming investor relations conferences in November. Details are as follows: STIFEL HEALTHCARE CONFERENCE (NEW YORK) Date: Tuesday, November 19,...

at 09:05
Exicure, Inc. , a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNAtm) technology, today announced that David Giljohann, chief executive officer Exicure, Inc. , has been named to Crain's Chicago Business...

at 09:02
Apixio Inc., the AI healthcare analytics company, is celebrating 10 years of AI-powered healthcare innovation and continued market penetration among top-tier health plans and providers. Having recently earned a spot on Deloitte's 2019 Technology Fast...

at 09:00
Ceapro Inc.  ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and...

at 09:00
eMDs announced today that it has broadened its relationship with DrFirst, one of the nation's leading providers of e-prescribing, patient medication management and price transparency solutions, to deliver new consumer-facing medication adherence...



News published on 21 october 2019 at 12:05 and distributed by: